Market PharmaPoint: Insomnia , Global Drug Forecast and Market Analysis to 2023
Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomo’s Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need. Read Complete Report with TOC: http://www.marketresearchstore.com/report/pharmapoint-insomnia-global-drug-forecast-and-market-13806
Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomo’s Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need.
Read Complete Report with TOC: http://www.marketresearchstore.com/report/pharmapoint-insomnia-global-drug-forecast-and-market-13806
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Market</strong> Research S<strong>to</strong>re<br />
<strong>PharmaPoint</strong>: <strong>Insomnia</strong> ,<br />
<strong>Global</strong> <strong>Drug</strong> <strong>Forecast</strong><br />
<strong>Market</strong><br />
Size, Share, <strong>Global</strong> Trends,<br />
<strong>Analysis</strong>, Research Report<br />
<strong>and</strong> <strong>Forecast</strong>,<br />
2015-<strong>2023</strong><br />
www.marketresearchs<strong>to</strong>re.com<br />
sales@marketresearchs<strong>to</strong>re.com
<strong>Market</strong> <strong>PharmaPoint</strong>: <strong>Insomnia</strong> , <strong>Global</strong> <strong>Drug</strong><br />
<strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong><br />
<strong>Insomnia</strong> is the most common sleep disorder <strong>and</strong> is believed <strong>to</strong> affect<br />
approximately 35% of the global population. The condition can be defined<br />
as patient-reported difficultly with sleep initiation or sleep maintenance<br />
which can include frequent awakenings, difficulty returning <strong>to</strong> sleep after<br />
awakenings, or awakening <strong>to</strong>o early with inability <strong>to</strong> return <strong>to</strong> sleep.<br />
Cases of insomnia can be classified on the basis of etiology in<strong>to</strong> primary<br />
<strong>and</strong> secondary (or comorbid) subtypes. The insomnia market is widely<br />
genericized creating a competitive environment for new products. As<br />
such, the treatment algorithm centers on the generically available
nonbenzodiazepines <strong>and</strong> low-dose sedating antidepressants, despite the<br />
launch of numerous novel agents. The value of the insomnia market is<br />
set <strong>to</strong> further decline following the loss of exclusivity for<br />
Sunovion/Dainippon Sumi<strong>to</strong>mo’s Lunesta, the <strong>to</strong>p selling insomnia drug,<br />
in April 2014. However, <strong>Global</strong>Data expects the launch of two pipeline<br />
products from a novel class of drugs <strong>to</strong> provide growth in the insomnia<br />
market as they may address some of the unmet need.<br />
Read Complete Report with TOC:<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-insomniaglobal-drug-forecast-<strong>and</strong>-market-13806
Highlights<br />
Key Questions Answered<br />
‣ The insomnia market is dominated by the generic<br />
nonbenzodiazepines <strong>and</strong> low-does sedating antidepressants. Novel<br />
products have not had a significant impact on this market as they<br />
lack notable clinical advantages over the current first-line drugs.<br />
What are the unmet needs in light of this? Will there be<br />
opportunities in this market for drug developers throughout the<br />
forecast period?<br />
‣ The current late stage insomnia pipeline is sparse with only one drug
having advanced <strong>to</strong> Phase III. However, <strong>Global</strong>Data believes two<br />
orexin recep<strong>to</strong>r antagonists will enter the market during the forecast<br />
period. What impact will these drugs have on the market? How will<br />
they affect the treatment algorithm for insomnia? Will these drugs<br />
fulfil any of the unmet needs for insomnia?<br />
‣ Population aging is occurring in almost all countries worldwide,<br />
particularly in the 7MM. This is expected <strong>to</strong> have a significant impact<br />
on the prevalence of insomnia. How will epidemiological changes<br />
impact the growth of the future insomnia market?<br />
Key Findings
‣ The main driver of growth in the insomnia market will be the<br />
introduction of the orexin recep<strong>to</strong>r antagonists over the<br />
forecast period. The launch of this novel drug class may<br />
address some of the unmet need in the insomnia market due <strong>to</strong><br />
the safety profile of these drugs <strong>and</strong> the availability of longterm<br />
clinical trial data.<br />
‣ The generic erosion of Lunesta within the insomnia market will<br />
lead <strong>to</strong> a decline in market size prior <strong>to</strong> the entry of pipeline<br />
products. The availability of generic eszopiclone could greatly<br />
affect the treatment algorithm <strong>and</strong> will put downward pricing<br />
pressure on the controlled-release zolpidem generics.<br />
‣ The biggest barrier for growth in the insomnia market will be
fierce competition from generic products. The commercial<br />
advantages <strong>to</strong> prescribing generic drugs will make it difficult for<br />
novel products <strong>to</strong> gain traction.<br />
‣ Considerable opportunity remains for products that meet the<br />
unmet needs in the insomnia market. <strong>Drug</strong>s with improved<br />
safety, which is sustained over the long-term, would hold a<br />
competitive advantage. Similarly, drugs that improve sleep<br />
quality would be viewed favorably by physicians.<br />
Read Complete Report with TOC:<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-insomniaglobal-drug-forecast-<strong>and</strong>-market-13806
Scope<br />
‣ Overview of insomnia, including epidemiology, etiology,<br />
pathophysiology, symp<strong>to</strong>ms, diagnosis, <strong>and</strong> treatment<br />
guidelines.<br />
‣ Annualized insomnia market revenue, annual cost of therapy<br />
<strong>and</strong> treatment usage pattern data from 2013 <strong>and</strong> forecast for<br />
ten years <strong>to</strong> <strong>2023</strong>.<br />
‣ Key <strong>to</strong>pics covered include market characterization, unmet<br />
needs, R&D <strong>and</strong> clinical trials assessment, late stage clinical<br />
trial analysis <strong>and</strong> implications for the insomnia therapeutics
market.<br />
‣ Pipeline analysis: focus on the three late-stage pipeline<br />
insomnia drugs discussing emerging trends as well as overview<br />
of earlier phase drugs.<br />
‣ <strong>Analysis</strong> of the current <strong>and</strong> future market competition in the<br />
global insomnia therapeutics market. Insightful review of the<br />
key industry drivers, restraints <strong>and</strong> challenges. Each trend is<br />
independently researched <strong>to</strong> provide qualitative analysis of its<br />
implications.
Reasons <strong>to</strong> buy<br />
‣ Develop <strong>and</strong> design your in-licensing <strong>and</strong> out-licensing<br />
strategies through a review of pipeline products <strong>and</strong><br />
technologies, <strong>and</strong> by identifying the companies with the most<br />
robust pipeline.<br />
‣ Additionally a list of acquisition targets included in the pipeline<br />
product company list.<br />
‣ Develop business strategies by underst<strong>and</strong>ing the trends<br />
shaping <strong>and</strong> driving the global insomnia therapeutics market.<br />
‣ Drive revenues by underst<strong>and</strong>ing the key trends, innovative<br />
products <strong>and</strong> technologies, market segments, <strong>and</strong> companies
likely <strong>to</strong> impact the global insomnia therapeutics market in<br />
future.<br />
‣ Formulate effective sales <strong>and</strong> marketing strategies by<br />
underst<strong>and</strong>ing the competitive l<strong>and</strong>scape <strong>and</strong> by analysing the<br />
performance of various competi<strong>to</strong>rs.<br />
‣ Identify emerging players with potentially strong product<br />
portfolios <strong>and</strong> create effective counter-strategies <strong>to</strong> gain a<br />
competitive advantage.<br />
‣ Track drug sales in the global insomnia therapeutics market<br />
from 2013-<strong>2023</strong>.
Get Sample Copy of Report:<br />
http://www.marketresearchs<strong>to</strong>re.com/report/pharmapoint-insomniaglobal-drug-forecast-<strong>and</strong>-market-13806#requestSample<br />
1 Table of Contents<br />
1 Table of Contents 10<br />
1.1 List of Tables 16<br />
1.2 List of Figures 22<br />
2 Introduction 25<br />
2.1 Catalyst 25<br />
2.2 Related Reports 25
3 Disease Overview 26<br />
3.1 Etiology <strong>and</strong> Pathophysiology 26<br />
3.1.1 Etiology 26<br />
3.1.2 Pathophysiology 32<br />
3.2 Classification 33<br />
3.3 Symp<strong>to</strong>ms 36<br />
3.4 Prognosis 37<br />
4 Epidemiology 38<br />
4.1 Disease Background 38<br />
4.2 Risk Fac<strong>to</strong>rs <strong>and</strong> Comorbidities 38
4.3 <strong>Global</strong> Trends 39<br />
4.4 <strong>Forecast</strong> Methodology 41<br />
4.4.1 Sources Used 47<br />
4.4.2 Sources Not Used 48<br />
4.4.3 <strong>Forecast</strong> Assumptions <strong>and</strong> Methods 49<br />
4.5 Epidemiological <strong>Forecast</strong> for Acute <strong>Insomnia</strong> (2013-<strong>2023</strong>) 58<br />
4.5.1 Total Prevalent Cases of Acute <strong>Insomnia</strong> 58<br />
Read More: http://www.marketresearchs<strong>to</strong>re.com/report/pharmapointinsomnia-global-drug-forecast-<strong>and</strong>-market-13806
About Us<br />
<strong>Market</strong> Research S<strong>to</strong>re is a single destination for all the industry,<br />
company <strong>and</strong> country reports. We feature large reposi<strong>to</strong>ry of latest<br />
industry reports, leading <strong>and</strong> niche company profiles, <strong>and</strong> market<br />
statistics released by reputed private publishers <strong>and</strong> public<br />
organizations.<br />
Contact Us<br />
TELEPHONE: +1-386-310-3803 Us:Stay<br />
With<br />
E-MAIL:<br />
sales@marketresearchs<strong>to</strong>re.com<br />
Suite #8138, 3422 SW<br />
15 Street,<br />
Deerfield Beach, Florida<br />
33442<br />
United States
Change language